BRIEF-Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018
* Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis
April 21 Zomedica Pharmaceuticals Corp
* Zomedica Pharmaceuticals Corp - files for resale of up to 76.6 million shares of co's common stock by the selling shareholders - sec filing Source text : bit.ly/2p044CE Further company coverage:
May 25 U.S. stocks rose on Thursday, with the S&P 500 and Nasdaq Composite scaling new highs, buoyed by strong earnings reports from the embattled retailer sector.
* Optibase ltd - revenues from fixed income real estate totaled $4 million for quarter ended march 31, 2017, compared to revenues of $4 million for q1 of 2016. Source text for Eikon: Further company coverage: